Submit a Comment

Opdivo Making Strides in Advanced Hepatocellular Carcinoma

  1. Bruix J, Merle P, Granito A, et al., “Efficacy, safety, and health related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, double blind phase 3 RESORCE trial;” Abstract LBA28, ESMO, 2016.
  2. Llovet J, Ricci S, Mazzaferro V et al., “Sorafenib in advanced hepatocellular carcinoma;” N Engl J Med 359(4): 378-90, 2008.
  3. Kantar Health, CancerMPact® Patient Metrics, accessed January 20, 2016. Available at www.cancermpact.com.
  4. Melero I, Sangro B, Yau T, et al., “Safety and preliminary efficacy of nivolumab (nivo) in patients with advanced hepatocellular carcinoma: Interim analysis of the phase ½ CheckMate-040 study;” Abstract 615O ESMO, Oct 9, 2016.
  5. Melero I, Sangro B, Yau T, et al., “Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study;” J Clin Oncol, 35:  (suppl 4S; abstract 226), 2017.
  6. Javle M, “Hepatobiliary Cancer; HCC: Checkpoint Inhibition;” Discussant of Abstract 226; Proc Amer Soc Clin Oncol Gastrointest Canc Sym, 2017.

Post a Comment

Your email is never shared. Required fields are marked *